The authors reply
- PMID: 36661472
- DOI: 10.1097/CCM.0000000000005763
The authors reply
Conflict of interest statement
Dr. Kiser’s institution received funding from the Department of Clinical Pharmacy at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences (to Dr. Kiser), and, in part, by the Colorado Clinical and Translational Science Award (grant UL1 TR002535) from the National Center for Advancing Translational Sciences/National Institutes of Health (NIH); he received support for article research form the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Comment on
-
After the Rebranding and Cost Increase, the Use of Vasopressin Continues to Increase Yearly Especially in Case of Acute Kidney Injury With Septic Shock: Is There Recent Data Justifying It?Crit Care Med. 2023 Feb 1;51(2):e68-e69. doi: 10.1097/CCM.0000000000005725. Epub 2023 Jan 20. Crit Care Med. 2023. PMID: 36661471 No abstract available.
References
-
- Honore PM, Redant S, Djimafo P, et al.: After the Rebranding and Cost Increase, the Use of Vasopressin Continues to Increase Yearly Especially in Case of Acute Kidney Injury With Septic Shock: Is There Recent Data Justifying It? Crit Care Med. 2023; 51:e68–e69
-
- Sacha GL, Kiser TH, Wright GC, et al.: Association between vasopressin rebranding and utilization in patients with septic shock. Crit Care Med. 2022; 50:644–654
-
- Sacha GL, Lam SW, Wang L, et al.: Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. Crit Care Med. 2022; 50:614–623
Publication types
LinkOut - more resources
Full Text Sources